GE Healthcare and Roche Partner to Develop Digital Diagnostics Platform
By Labmedica International staff writers
16 Jan 2018
GE Healthcare (Chicago, IL, USA) and Roche (Basel, Switzerland) have entered into a strategic, long-term partnership to jointly develop and co-market digital clinical decision support solutions. Initially, the partnership will focus on products that accelerate and improve individualized treatment options for cancer and critical care patients.
GE Healthcare is a leading provider of medical imaging equipment, harnessing data and analytics across hardware, software and biotech. Roche is a pioneer in pharmaceuticals and diagnostics, and is the world’s largest biotech company, offering differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. The company is also a leader in the fields of in vitro diagnostics and tissue-based cancer diagnostics, and is a frontrunner in diabetes management.
Together, the companies will focus on developing the first digital platform in the industry, using advanced analytics to provide workflow solutions and apps that support clinical decisions. This will enable seamless integration and analysis of in-vivo and in-vitro data, patient records, medical best practice, real time monitoring and the latest research outcomes. This will also provide comprehensive decision support to clinicians for offering the right treatment and quality of care for their patients.
For instance, oncology care teams with multiple specialists will be able to access a comprehensive data dashboard to review, collaborate and align on treatment decisions for cancer patients at each stage of their disease. Similarly, in the critical care setting, data from a patient’s hospital monitoring equipment will be integrated with their biomarker, genomic and sequencing data to help physicians identify, or even predict severe complications before they arise.
“This unique partnership will deliver innovative solutions and insights in clinical decision-making,” said Roland Diggelmann, CEO Roche Diagnostics. “Our goal is to support clinicians and other relevant stakeholders for the benefit of patients by providing the right decision support at the right time and through comprehensive digital offerings.”
“This is the first time that two major players in healthcare have combined digital, in-vivo and in-vitro diagnostics to this degree,” said Kieran Murphy, President and CEO of GE Healthcare. “We believe this alliance will help accelerate the delivery of data-driven precision health for customers, patients and the healthcare industry.”